TheraRadar
← Back
Data updated: Jul 17, 2026

LAB SALVAT

Pharma
Infectious DiseaseDermatology Execution: Excellent

LAB SALVAT is a pharmaceutical company focused on Infectious Disease, Dermatology. Key products include OTOVEL.

2009
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

LAB SALVAT at a Glance

  • Strong track record with 90% execution quality across 11 trials
  • Fast trial execution (17 months median completion)

LAB SALVAT's Key Drugs

LAB SALVAT's core commercial portfolio centers on OTOVEL, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.

OTOVEL
Ophthalmology

Bacterial Conjunctivitis

Approved 2016

LAB SALVAT's Recent FDA Approvals

New NDA/BLA approvals for LAB SALVAT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LAB SALVAT's Therapeutic Areas

LAB SALVAT's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 75%
2 drugs
Dermatology 25%
0 drugs Phase 3: 1

LAB SALVAT's Top Competitors

LAB SALVAT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology
BAUSCH AND LOMB INC other
Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology

LAB SALVAT Pipeline Snapshot

LAB SALVAT has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.

1
Phase 3
0
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OTOVEL leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 9/10 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges